PubMed · 15837617
JAKing up hematopoietic proliferation.
Abstract
Mutations that deregulate proliferation and survival pathways have emerged as a common molecular theme in the pathogenesis of myeloproliferative disorders (MPDs). Three studies now report an amino acid substitution in the JAK2 kinase in most patients with polycythemia vera as well as in some cases of essential thrombocythemia and chronic idiopathic myelofibrosis. Functional analysis demonstrates that this mutation confers erythropoietin-independent growth in vitro, deregulates signaling pathways downstream of JAK2, and causes polycythemia in mice. These results open new avenues for diagnosing and classifying patients with these disorders, and identify a new molecular target for drug discovery.
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Kevin Shannon, Richard A Van Etten. 2005. JAKing up hematopoietic proliferation.. https://doi.org/10.1016/j.ccr.2005.04.002
Cite the original work for its findings. Save a collection to share your selection of sources.